Related references
Note: Only part of the references are listed.The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis
Camille Roubille et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Iain B. McInnes et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Disease assessment in psoriatic spectrum: a modular approach for use in routine clinical practice
Julekha Wajed et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials
Radjiv Goulabchand et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double- blind randomised placebo- controlled study (RAPID-PsA)
P. J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative
Laure Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Predictors of functional deterioration in Chinese patients with Psoriatic arthritis: a longitudinal study
Ying-Ying Leung et al.
BMC MUSCULOSKELETAL DISORDERS (2014)
A review of disease activity measures for psoriatic arthritis: what is the best approach?
Minyoung Her et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: A two-year prospective observational study
Roberta Ramonda et al.
JOINT BONE SPINE (2014)
A Systematic Literature Review on the Application of Rasch Analysis in Musculoskeletal Disease - A Special Interest Group Report of OMERACT 11
Ying-Ying Leung et al.
JOURNAL OF RHEUMATOLOGY (2014)
Updated Guidelines for the Management of Axial Disease in Psoriatic Arthritis
Peter Nash et al.
JOURNAL OF RHEUMATOLOGY (2014)
Development of a Disease Activity and Responder Index for Psoriatic Arthritis - Report of the Psoriatic Arthritis Module at OMERACT 11
Laura C. Coates et al.
JOURNAL OF RHEUMATOLOGY (2014)
Safety and Efficacy of Therapies for Skin Symptoms of Psoriasis in Patients with Psoriatic Arthritis: A Systematic Review
Wolf-Henning Boehncke et al.
JOURNAL OF RHEUMATOLOGY (2014)
Comprehensive Treatment of Dactylitis in Psoriatic Arthritis
Shawn Rose et al.
JOURNAL OF RHEUMATOLOGY (2014)
Comprehensive Treatment of Psoriatic Arthritis: Managing Comorbidities and Extraarticular Manifestations
Alexis Ogdie et al.
JOURNAL OF RHEUMATOLOGY (2014)
Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review
Maria Laura Acosta Felquer et al.
JOURNAL OF RHEUMATOLOGY (2014)
Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis
Ana-Maria Orbai et al.
JOURNAL OF RHEUMATOLOGY (2014)
The risks and benefits of glucocorticoid treatment for tendinopathy: A systematic review of the effects of local glucocorticoid on tendon
Benjamin John Floyd Dean et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2014)
High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires
Muhammad Haroon et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
EXTENDED REPORT Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review
Anna Jamnitski et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis
Laura C. Coates et al.
BMC MUSCULOSKELETAL DISORDERS (2013)
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis
S. Fenix-Caballero et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2013)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
Risk of Non-Hodgkin's Lymphoma in Primary Sjogren's Syndrome: A Population-Based Study
Svein J. Johnsen et al.
ARTHRITIS CARE & RESEARCH (2013)
Leflunomide in Psoriatic Arthritis: Results From a Large European Prospective Observational Study
Frank Behrens et al.
ARTHRITIS CARE & RESEARCH (2013)
Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
Asta Baranauskaite et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis
Zoe Ash et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
L. Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden early arthritis cohort
Rosaline van den Berg et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Consensus Guidelines for the Management of Plaque Psoriasis
Sylvia Hsu et al.
ARCHIVES OF DERMATOLOGY (2012)
Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis
Laura C. Coates et al.
ARTHRITIS AND RHEUMATISM (2012)
Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2012)
Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus
R. G. Langley et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2012)
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells
Jonathan P. Sherlock et al.
NATURE MEDICINE (2012)
Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Craig Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis
Gabrielle H. Kingsley et al.
RHEUMATOLOGY (2012)
Clinical outcomes in psoriatic arthritis: A systematic literature review
Penelope Esther Palominos et al.
ARTHRITIS CARE & RESEARCH (2012)
Cardiovascular Risk in Patients with Psoriatic Arthritis
Tracy Y. Zhu et al.
INTERNATIONAL JOURNAL OF RHEUMATOLOGY (2012)
Measuring Disease Activity in Psoriatic Arthritis
Priscilla C. H. Wong et al.
INTERNATIONAL JOURNAL OF RHEUMATOLOGY (2012)
Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study
Lai-Shan Tam et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Carotid Intima-Media Thickness in Psoriatic Arthritis Differences Between Tumor Necrosis Factor-α Blockers and Traditional Disease-Modifying Antirheumatic Drugs
Matteo Nicola Dario Di Minno et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Atherosclerosis in psoriatic arthritis
R. Ramonda et al.
AUTOIMMUNITY REVIEWS (2011)
Evaluation of spinal mobility measurements in predicting axial psoriatic arthritis
Ying-ying Leung et al.
CLINICAL RHEUMATOLOGY (2011)
Differential Features Between Primary Ankylosing Spondylitis and Spondylitis Associated with Psoriasis and Inflammatory Bowel Disease
Rodolfo Perez Alamino et al.
JOURNAL OF RHEUMATOLOGY (2011)
Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program
Dafna D. Gladman et al.
RHEUMATOLOGY (2011)
Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis
Janice A. Husted et al.
ARTHRITIS CARE & RESEARCH (2011)
Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)
Alexandra N. Colebatch et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2011)
Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment
L. C. Coates et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide
J. R. Curtis et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
M. J. L. Peters et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Obesity in Early Adulthood as a Risk Factor for Psoriatic Arthritis
Razieh Soltani-Arabshahi et al.
ARCHIVES OF DERMATOLOGY (2010)
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs
Mariangela Atteno et al.
CLINICAL RHEUMATOLOGY (2010)
Socioeconomic Burden of Psoriatic Arthritis in Hong Kong: Direct and Indirect Costs and the Influence of Disease Pattern
Tracy Y. Zhu et al.
JOURNAL OF RHEUMATOLOGY (2010)
Evaluation of the CASPAR criteria for psoriatic arthritis in the Chinese population
Ying Y. Leung et al.
RHEUMATOLOGY (2010)
Predictors of response to intra-articular steroid injection in psoriatic arthritis
Lihi Eder et al.
RHEUMATOLOGY (2010)
Validation of Minimal Disease Activity Criteria for Psoriatic Arthritis Using Interventional Trial Data
Laura C. Coates et al.
ARTHRITIS CARE & RESEARCH (2010)
Treatment recommendations for psoriatic arthritis
C. T. Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
P. J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2009)
Incidence and Clinical Predictors of Psoriatic Arthritis in Patients With Psoriasis: A Population-Based Study
Floranne C. Wilson et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment
M. Brenner et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis
V. Ravindran et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis
Paul J. Healy et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate
Raffaele Scarpa et al.
CLINICAL RHEUMATOLOGY (2008)
Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis
Vinod Chandran et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis
Alan J. Kivitz et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2007)
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial
A. Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Adalimumab for long-term treatment of psoriatic arthritis - Forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial
Dafna D. Gladman et al.
ARTHRITIS AND RHEUMATISM (2007)
Classification criteria for psoriatic arthritis - Development of new criteria from a large international study
William Taylor et al.
ARTHRITIS AND RHEUMATISM (2006)
The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year
A. Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2005)
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
C Antoni et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Classification and diagnostic criteria for psoriatic arthritis
PS Helliwell et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
SP McKenna et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Etanercept treatment of psoriatic arthritis - Safety, efficacy, and effect on disease progression
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2004)
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis - A multinational, double-blind, randomized, placebo-controlled clinical trial
JP Kaltwasser et al.
ARTHRITIS AND RHEUMATISM (2004)
The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites
M Benjamin et al.
JOURNAL OF ANATOMY (2001)
Share Paper
